Amgen Inc (AMGN) operating KPIs
AMGNNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026Score 17/3039% above fair value
$466.01+5.28 (+1.15%)
Close on Oct 30, 2026Market cap $251.94BP/E 28.9Yield 2.07%
Amgen beiGene / BeOne Medicines — Amgen Equity Ownership Stake (%) (%)
Form 10-Q / 10-K Investments & Collaborations Note (XBRL)
Latest, Q2 2026
17.0%
Period ended Jun 30, 2026
Change on a year earlier
–
History
11 quarters
Since Q4 2019
Sources
9
Documents cited below
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | BeiGene / BeOne Medicines — Amgen Equity Ownership Stake (%) (%) | Year on year | Source |
|---|---|---|---|---|
| Q2 2026 | Jun 30, 2026 | 17.0% | – | Form 10-Q (filed 2026-08-05) ↗ |
| Q1 2026 | Mar 31, 2026 | 17.0% | – | Form 10-Q (filed 2026-05-01) ↗ |
| Q4 2025 | Dec 31, 2025 | 17.0% | -0.8 pts | Form 10-Q (filed 2026-08-05) ↗ |
| Q4 2024 | Dec 31, 2024 | 17.8% | -0.2 pts | Form 10-K (filed 2026-02-13) ↗ |
| Q3 2024 | Sep 30, 2024 | 18.0% | – | Form 10-Q (filed 2024-10-31) ↗ |
| Q2 2024 | Jun 30, 2024 | 18.0% | – | Form 10-Q (filed 2024-08-07) ↗ |
| Q4 2023 | Dec 31, 2023 | 18.0% | -0.2 pts | Form 10-Q (filed 2024-10-31) ↗ |
| Q4 2022 | Dec 31, 2022 | 18.2% | -0.2 pts | Form 10-K (filed 2024-02-14) ↗ |
| Q3 2022 | Sep 30, 2022 | 18.2% | – | Form 10-Q (filed 2022-11-04) ↗ |
| Q4 2021 | Dec 31, 2021 | 18.4% | – | Form 10-K (filed 2023-02-09) ↗ |
| Q4 2019 | Dec 31, 2019 | 20.5% | – | Form 10-K (filed 2025-02-14) ↗ |
Cite this data
StockData. (2026). Amgen BeiGene / BeOne Medicines — Amgen Equity Ownership Stake (%) (%), quarterly Q4 2019–Q2 2026 [Data set]. Compiled from Amgen SEC filings and investor materials. https://stockdatahq.com/stocks/amgn/kpis/collab_beigene_own_pct
See every metric in the Amgen KPI table. Data updated Oct 28, 2026.